# A Safety Study of LY2886721 Single Doses in Healthy Subjects

> **NCT01133405** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 40 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** LY2886721
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01133405
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01133405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01133405, "A Safety Study of LY2886721 Single Doses in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01133405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*